Effects of SUlodexide on Postprandial lipidmetabolism in patiEnts with diabetes mellitus type II; Reversing dyslipidemia

Effects of SUlodexide on Postprandial lipidmetabolism in patiEnts with diabetes mellitus type II; Reversing dyslipidemia - SUPER study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON41342

Enrollment

Registered

2012-05-31

Start date

2014-04-22

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholesterol diabetes

Interventions

Sulodexide is a commercially available oral heparanoid compound consisting of heparan sulphate (80%) and dermatan sulphate (20%)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male - Age between 18 and 65 years - willing to stop ATII/ACE inhibitors 5 days before each lipidload;- oral antidiabetes medication and on statin therapy (no insulin therapy)

Exclusion criteria

Exclusion criteria: - Smoking;- Immunosuppressive drugs;- Serious previous illnesses;- Coagulation disorder;- Primary dyslipidemias;- BMI > 33 kg/m2;- Hypertension (systolic > 140 mm Hg or diastolic > 90 mm Hg);- Cardiovascular disease: ;- AMI;- CVA/ TIA;- AP ;- Intermittent claudication ;- Aneurysms of the aorta

Design outcomes

Primary

Measure	Time frame
Aim of the study is to investigate whether 2 months of oral sulodexide treatment normalizes postprandial hypertriglyceridemia in patients with DM type II on statin treatment.	—

Secondary

Measure	Time frame
The second objective of the present study is to measure the effect of sulodexide on adipose tissue markers of lipolysis (ANGLPTL3, GPIHBP1 and LPL) in relation to periferal lipolysis (heparin challenge for LPL release)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)